Research & Literature

Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits.

Larsen CP, Messias NC, Walker PD, et al.

Kidney international 2015; (88(4)):867-73 doi:10.1038/ki.2015.195.

Renal interstitial mast cell count is significantly higher in membranoproliferative glomerulonephritis than in class IV lupus nephritis.

Kaczmarczyk K, Musiał J, Soja J, et al.

Polish journal of pathology : official journal of the Polish Society of Pathologists 2015; (66(2)):149-53 doi:10.5114/pjp.2015.53011.

AJKD Atlas of Renal Pathology: Membranoproliferative Glomerulonephritis.

Fogo AB, Lusco MA, Najafian B, Alpers CE

American journal of kidney diseases : the official journal of the National Kidney Foundation 2015; (66(3)):e19-20.

Diagnosis of complement alternative pathway disorders.

Angioi A, Fervenza FC, Sethi S, et al.

Kidney international 2016; (89(2)):278-88.

Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis.

Kawasaki Y, Kanno S, Ono A, et al.

Pediatric nephrology (Berlin, Germany) 2016; (31(7)):1091-9 doi:10.1007/s00467-015-3307-z.

Clinical and pathological considerations on renal diseases in patients with chronic viral hepatitis.

Iovănescu VF, Constantinescu AF, Streba CT, et al.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2016; (57(2)):401-6.

A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.

Obata F, Murakami T, Miyagi J, et al.

CEN case reports 2017; (6(1)):55-60 doi:10.1007/s13730-016-0244-z.

Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

Rudnicki M

BioMed research international 2017; (2017()):2180508 doi:10.1155/2017/2180508.

Membranoproliferative Glomerulonephritis Associated with a Human Immunodeficiency Virus Infection.

Rafik H, El Amrani M, El Kabbaj D

Indian journal of nephrology 2017; (27(4)):319-320 doi:10.4103/0971-4065.202838.

Case Report of Spontaneous Remission of Biopsy-Proven Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

Shah R, Segal MS, Wilkowski MJ

Case reports in nephrology and dialysis 2017; (7(2)):81-90 doi:10.1159/000477660.

Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015.

Nakagawa N, Hasebe N, Hattori M, et al.

Clinical and experimental nephrology 2018; (22(4)):797-807 doi:10.1007/s10157-017-1513-7.

De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?

Abbas F, El Kossi M, Jin JK, et al.

World journal of transplantation 2017; (7(6)):285-300 doi:10.5500/wjt.v7.i6.285.

Clinical and histological features of patients with membranoproliferative glomerulonephritis classified by immunofluorescence findings.

Dias CB, Testagrossa L, Jorge L, et al.

Jornal brasileiro de nefrologia 2017; (39(4)):447-453 doi:10.5935/0101-2800.20170078.

The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Sethi S, Rajkumar SV, D'Agati VD

Journal of the American Society of Nephrology : JASN 2018; (29(7)):1810-1823 doi:10.1681/ASN.2017121319.

C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

Alonso-Titos J, Perea-Ortega L, Sola E, et al.

BMC nephrology 2018; (19(1)):129 doi:10.1186/s12882-018-0927-0.

Rituximab treatment for immune-complex-mediated membranoproliferative glomerulonephritis.

Lu Q, Zuo L, Dong B, et al.

Immunotherapy 2018; (10(12)):1027-1031 doi:10.2217/imt-2018-0031.

Mixed cryoglobulinemic membranoproliferative glomerulonephritis due to monoclonal gammopathy of undetermined significance: A case report.

Hsu JH, Fang YW, Yang AH, Tsai MH

Medicine 2018; (97(37)):e12416 doi:10.1097/MD.0000000000012416.

Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report.

Rana R, Cockwell P, Vydianath B, et al.

Mayo Clinic proceedings. Innovations, quality & outcomes 2018; (2(3)):297-302 doi:10.1016/j.mayocpiqo.2018.04.003.

Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.

Holle J, Berenberg-Goßler L, Wu K, et al.

Pediatric nephrology (Berlin, Germany) 2018; (33(12)):2289-2298 doi:10.1007/s00467-018-4034-z.

Idiopathic membranoproliferative glomerulonephritis treated with mycophenolate mofetil.

Koratala A, Malpartida FR, Lee Loy J, Zeng X

Clinical case reports 2018; (6(11)):2287-2288 doi:10.1002/ccr3.1826.

[Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].

Gödecke V, Schmidt JJ, Bräsen JH, et al.

Der Internist 2019; (60(1)):10-22 doi:10.1007/s00108-018-0538-7.

C3 glomerulopathy - understanding a rare complement-driven renal disease.

Smith RJH, Appel GB, Blom AM, et al.

Nature reviews. Nephrology 2019; (15(3)):129-143 doi:10.1038/s41581-018-0107-2.

Membranoproliferative glomerulonephritis in Russian population.

Dobronravov VA, Smirnov AV

Terapevticheskii arkhiv 2018; (90(12)):39-47 doi:10.26442/00403660.2018.12.000007.

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

Schubart A, Anderson K, Mainolfi N, et al.

Proceedings of the National Academy of Sciences of the United States of America 2019; (116(16)):7926-7931 doi:10.1073/pnas.1820892116.

[Monoclonal gammopathy of renal significance and membranoproliferative glomerulonephritis: a complex relationship with promising therapeutic opportunities].

Manes M, Radin E, Pellu' V, et al.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 2019; (36(4)).

A case report of recurrent membranoproliferative glomerulonephritis after kidney transplantation due to ventriculoatrial shunt infection.

Völker LA, Burkert K, Scholten N, et al.

BMC nephrology 2019; (20(1)):296 doi:10.1186/s12882-019-1472-1.

Utility of immunohistochemistry with C3d in C3 glomerulopathy.

Snijders MLH, van de Wall-Neecke BJ, Hesselink DA, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020; (33(3)):431-439 doi:10.1038/s41379-019-0348-z.

Diagnostic Yield of Next-Generation Sequencing in Patients With Chronic Kidney Disease of Unknown Etiology.

de Haan A, Eijgelsheim M, Vogt L, et al.

Frontiers in genetics 2019; (10()):1264 doi:10.3389/fgene.2019.01264.

Infection-related Glomerulonephritis and C3 Glomerulonephritis - Similar Yet Dissimilar: A Case Report and Brief Review of Current Literature.

Chamarthi G, Clapp WL, Bejjanki H, et al.

Cureus 2020; (12(2)):e7127 doi:10.7759/cureus.7127.

Rare case of post-varicella membranoproliferative glomerulonephritis presenting with massive proteinuria.

Majumdar A, Atam V, Mishra M

BMJ case reports 2020; (13(3)) doi:10.1136/bcr-2019-233084.

Mycophenolate Mofetil Treatment of C3 Glomerulopathy.

Peleg Y, Appel GB

Clinical journal of the American Society of Nephrology : CJASN 2020; (15(9)):1234-1236 doi:10.2215/CJN.11740720.

Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.

Khandelwal P, Bhardwaj S, Singh G, et al.

Pediatric nephrology (Berlin, Germany) 2021; (36(3)):591-600 doi:10.1007/s00467-020-04736-8.

A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab.

Kuang C, Quann K, Liman AK, et al.

Clinical case reports 2020; (8(10)):1984-1987 doi:10.1002/ccr3.3044.

Immune Thrombocytopenic Purpura Complicated by Hepatitis C Virus-related Membranoproliferative Glomerulonephritis after Rituximab Therapy.

Kubodera A, Kume A, Hayashi K, et al.

Internal medicine (Tokyo, Japan) 2021; (60(15)):2469-2473 doi:10.2169/internalmedicine.6758-20.

Hepatitis C-related membranoproliferative glomerulonephritis in the era of direct antiviral agents.

Abdelhamid WAR, Shendi A, Zahran M, et al.

Jornal brasileiro de nefrologia 2022; (44(2)):291-295 doi:10.1590/2175-8239-JBN-2020-0148.

A clinical approach to children with C3 glomerulopathy.

Vivarelli M, van de Kar N, Labbadia R, et al.

Pediatric nephrology (Berlin, Germany) 2022; (37(3)):521-535 doi:10.1007/s00467-021-05088-7.

Ultra-rare renal diseases diagnosed with whole-exome sequencing: Utility in diagnosis and management.

Jung J, Lee JH, Park YS, et al.

BMC medical genomics 2021; (14(1)):177 doi:10.1186/s12920-021-01026-6.

Mesangiocapillary glomerulonephritis complicating pulmonary tuberculosis.

Torpiano P, Holwill S, Pace D

CEN case reports 2022; (11(1)):17-21 doi:10.1007/s13730-021-00626-6.

Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.

Nakagawa N, Mizuno M, Kato S, et al.

PloS one 2021; (16(9)):e0257397 doi:10.1371/journal.pone.0257397.

FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy.

Garam N, Cserhalmi M, Prohászka Z, et al.

Frontiers in immunology 2021; (12()):720183 doi:10.3389/fimmu.2021.720183.

Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children.

Xu L, Wei F, Feng J, et al.

Translational pediatrics 2021; (10(11)):2985-2996 doi:10.21037/tp-21-286.

Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation.

Caravaca-Fontán F, Polanco N, Villacorta B, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(1)):222-235 doi:10.1093/ndt/gfac148.

[Benefit of therapeutic drug monitoring of immunosuppressants and immunomodulators in the management of autoimmune diseases].

Djabarouti S, Mora P, Lahouati M, et al.

La Revue de medecine interne 2022; (43(7)):412-418 doi:10.1016/j.revmed.2022.03.343.

Monoclonal gammopathy of renal significance: Early diagnosis is key.

Alonso-Titos J, Martínez-Esteban MD, López V, et al.

Nefrologia 2021; (41(5)):502-513 doi:10.1016/j.nefroe.2021.11.008.

Cardiac Tamponade-Associated Dense Deposit Disease: A Case Report and Review of the Literature.

Al Zabali SM, Rubaihan AK, Alnetaifat MF, et al.

Cureus 2022; (14(9)):e29280 doi:10.7759/cureus.29280.

[Modern approaches to the detection of monoclonal gammopathy of undetermined significance (MGUS) in patients with kidney diseases].

Kozlovskaya Lysenko LV, Chebotareva NV, Mrykhin NN, et al.

Terapevticheskii arkhiv 2019; (91(6)):67-72 doi:10.26442/00403660.2019.06.000281.

An atypical anti-GBM disease complicated by idiopathic nodular glomerulosclerosis: Case report.

Qin J, Zhu T, Zhang H, Ou S

Clinical nephrology 2023; (99(2)):98-104 doi:10.5414/CN110962.

Immunohistochemistry May Not Replace Immunofluorescence in Paraffin-embedded Tissue for Detecting Masked Monoclonal Immunoglobulin Deposits.

Oda Y, Ikeda Y, Abe H, et al.

Internal medicine (Tokyo, Japan) 2023; (62(24)):3657-3661 doi:10.2169/internalmedicine.1117-22.

Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.

Wada Y, Kamata M, Miyasaka R, et al.

International journal of molecular sciences 2023; (24(9)) doi:10.3390/ijms24098432.

Genetic diagnosis of kidney disease by whole exome sequencing and its clinical application.

Jung J, Lee JH, Seo GH, et al.

Clinical genetics 2023; (104(3)):298-312 doi:10.1111/cge.14382.

Recurrent Membranoproliferative Glomerulonephritis After Kidney Transplantation: Risk Factors and Impact on Graft Survival.

de Paula LC, Mazzali M, de Sousa MV

Annals of transplantation 2023; (28()):e940502 doi:10.12659/AOT.940502.

C3G and Ig-MPGN-treatment standard.

Noris M, Remuzzi G

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(2)):202-214 doi:10.1093/ndt/gfad182.

Association of monoclonal gammopathy of undetermined significance and C3 glomerulopathy.

Ekladious A, Bhandari R, Javaid MM

Internal medicine journal 2023; (53(9)):1712-1715 doi:10.1111/imj.16222.

[Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].

Rudnicki M, Windpessl M, Eller K, et al.

Wiener klinische Wochenschrift 2023; (135(Suppl 5)):688-695 doi:10.1007/s00508-023-02264-7.

Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Wong E, Nester C, Cavero T, et al.

Kidney international reports 2023; (8(12)):2754-2764 doi:10.1016/j.ekir.2023.09.017.

Direct immunofluorescence on formalin-fixed, paraffin-embedded versus fresh frozen human renal biopsies: a comparative study.

Eidan AJ

Journal of immunoassay & immunochemistry 2024; (45(3)):292-305 doi:10.1080/15321819.2024.2306324.

Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.

Vivarelli M, Bomback AS, Meier M, et al.

Kidney international reports 2024; (9(1)):64-72 doi:10.1016/j.ekir.2023.10.022.

To interpret and analyze the changing patterns of histology and direct immunofluorescence findings in membranoproliferative glomerulonephritis.

Nayak PP, Pradhan P, Pradhan D, et al.

Indian journal of pathology & microbiology 2024; (67(1)):80-85 doi:10.4103/ijpm.ijpm_1015_22.

Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.

Madden B, Singh RD, Haas M, et al.

Kidney international 2024; (105(5)):1077-1087 doi:10.1016/j.kint.2024.02.013.

Diagnostic Challenges and Emerging Pathogeneses of Selected Glomerulopathies.

Andeen NK, Hou J

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2024; (27(5)):387-410 doi:10.1177/10935266241237656.

Atypical anti-glomerular basement membrane disease with membranous hyperplasia: diagnostic challenges and treatment variability.

Tong R, Luo Z, Zhong X, et al.

BMC nephrology 2024; (25(1)):132 doi:10.1186/s12882-024-03571-5.

Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy.

Meuleman MS, Petitprez F, Pickering MC, et al.

Journal of the American Society of Nephrology : JASN 2024; (35(8)):1034-1044 doi:10.1681/ASN.0000000000000373.

Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.

Escudero-Saiz VJ, Gonzalez Á, García-Herrera A, et al.

Kidney medicine 2024; (6(6)):100823 doi:10.1016/j.xkme.2024.100823.

Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options.

Bartoli G, Dello Strologo A, Grandaliano G, Pesce F

International journal of molecular sciences 2024; (25(12)) doi:10.3390/ijms25126508.

Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype.

Roquigny J, Meuleman MS, El Sissy C, et al.

Journal of the American Society of Nephrology : JASN 2025; (36(2)):264-273 doi:10.1681/ASN.0000000000000499.

Vision transformer introduces a new vitality to the classification of renal pathology.

Zhang J, Lu JD, Chen B, et al.

BMC nephrology 2024; (25(1)):337 doi:10.1186/s12882-024-03800-x.

[What is proven in the treatment of complement-mediated kidney diseases?]

Kaufeld J, Lovric S

Innere Medizin (Heidelberg, Germany) 2024; (65(12)):1216-1224 doi:10.1007/s00108-024-01812-1.

A Case of Myeloperoxidase Antineutrophil Cytoplasmic Antibody (MPO-ANCA)-Positive Membranoproliferative Glomerulonephritis With Latent Tuberculosis Infection.

Murakami A, Gotoda H, Nakamoto T, et al.

Cureus 2024; (16(10)):e72063 doi:10.7759/cureus.72063.

Renal manifestations of MGUS.

Bridoux F, Nasr SH, Arnulf B, et al.

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):489-498 doi:10.1182/hematology.2024000573.

Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy.

Bomback AS, Charu V, Fakhouri F

Kidney international reports 2025; (10(1)):17-28 doi:10.1016/j.ekir.2024.09.017.

Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.

Bomback AS, Daina E, Remuzzi G, et al.

Kidney international reports 2025; (10(1)):87-98 doi:10.1016/j.ekir.2024.09.030.

Clinical features and outcomes of immune complex-membranoproliferative glomerulonephritis and C3 glomerulopathy: a multicenter observational cohort study analyzing kidney biopsy cases.

Kim S, Choi YE, Kim SG, et al.

Kidney research and clinical practice 2024; doi:10.23876/j.krcp.24.129.

Clinical characteristics and short term outcomes of childhood immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy: a single centre retrospective study.

Bajeer IA, Khatri S, Kumar P, et al.

BMC nephrology 2025; (26(1)):143 doi:10.1186/s12882-025-04078-3.

Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations.

Lafayette RA, Charu V, Glassock RJ

Advances in therapy 2025; (42(5)):2003-2014 doi:10.1007/s12325-025-03167-x.

The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment

Perry C, Von Buttlar X, Thota S

Turkish journal of haematology : official journal of Turkish Society of Haematology 2025; (42(2)):74-81 doi:10.4274/tjh.galenos.2025.2025.0054.

Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.

Caravaca-Fontán F, Toledo-Rojas R, Huerta A, et al.

Kidney international reports 2025; (10(4)):1223-1236 doi:10.1016/j.ekir.2025.01.024.

Repeated Kidney Biopsy in Membranoproliferative Glomerulonephritis.

Li AH, Li Y, Li MS, et al.

Kidney diseases (Basel, Switzerland) 2025; (11(1)):258-269 doi:10.1159/000545727.

Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN.

Ghaddar M, Caravaca-Fontán F, Praga M, et al.

Clinical journal of the American Society of Nephrology : CJASN 2025; (20(8)):1119-1131 doi:10.2215/CJN.0000000751.

Crescentic glomerulonephritis associated with myelodysplatic syndrome and visceral leishmaniasis.

Decaestecker A, Daniel A, Malbranque Z, et al.

Journal of nephrology 2025; (38(7)):1999-2004 doi:10.1007/s40620-025-02329-y.

The Retinal Complications of C3 Dense Deposit Disease: A Scoping Review.

McCarney J, Curran K, Peto T, et al.

Vision (Basel, Switzerland) 2025; (9(3)) doi:10.3390/vision9030064.

Rare kidney disease registries: A scoping review on characteristics and lessons learnt.

Mahdian SZ, Hooman N, Sheikhtaheri A

Health information management : journal of the Health Information Management Association of Australia 2026; (55(1)):25-42 doi:10.1177/18333583251357802.

Structural characterization of Factor H via computational methods: Implications for disease and therapy.

Jena AB, Duttaroy AK

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2025; (192()):118628 doi:10.1016/j.biopha.2025.118628.

Hierarchical clustering uncovered disease patterns and further untangled complexities in immune complex-mediated idiopathic MPGN and C3 glomerulopathy.

Benigni A, Daina E, Löffler-Wirth H, et al.

Kidney international 2026; (109(1)):178-195 doi:10.1016/j.kint.2025.08.035.

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

Fakhouri F, Bomback AS, Ariceta G, et al.

The New England journal of medicine 2025; (393(22)):2210-2220 doi:10.1056/NEJMoa2501510.

Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative GN.

Caravaca-Fontan F, Norouzi S, Huang M, et al.

Kidney360 2026; (7(3)):547-559 doi:10.34067/KID.0000001059.

Electron Microscopy in Renal Biopsy Interpretation: When and Why It Still Matters.

Qasim H, Hayajneh Z, Khattab K, et al.

Cureus 2025; (17(11)):e96311 doi:10.7759/cureus.96311.

Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN.

Nanchen G, Marasà M, Breno M, et al.

Clinical journal of the American Society of Nephrology : CJASN 2026; (21(4)):626-640 doi:10.2215/CJN.0000000953.

Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

Caravaca-Fontán F, Fakhouri F, Licht C, et al.

Kidney international reports 2026; (11(2)):103671 doi:10.1016/j.ekir.2025.10.028.

Recurrence of C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis After Kidney Transplantation: Challenges and Opportunities.

Ruiz-Cabello JE, Trujillo H, Cavero T, et al.

Kidney international reports 2026; (11(2)):103682 doi:10.1016/j.ekir.2025.11.008.

Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.

Kavanagh D, Ariceta G, Vivarelli M, et al.

Kidney international reports 2026; (11(1)):17-31 doi:10.1016/j.ekir.2025.10.020.

Efficacy of iptacopan in idiopathic immune complex-mediated membranoproliferative glomerulonephritis refractory to conventional treatment.

López Hidalgo R, Caba Molina M, Ruiz Escolano FJ, et al.

Nefrologia 2026; (46(2)):501426 doi:10.1016/j.nefroe.2026.501426.

Initial treatment patterns of primary membranoproliferative glomerulonephritis in Japan (2017-2021): an updated analysis based on nationwide personal clinical records.

Nakagawa N, Hiromura K, Isaka Y

Clinical and experimental nephrology 2026; (30(4)):590-596 doi:10.1007/s10157-026-02828-7.

Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.

Filippone EJ, Farber JL

Frontiers in nephrology 2026; (6()):1747678 doi:10.3389/fneph.2026.1747678.

Pegcetacoplan-induced remission in pediatric immune-complex membranoproliferative glomerulonephritis with comorbid autosomal recessive polycystic kidney disease: a case report.

Alrasheed R, Alanazi A, Bukhari R, et al.

Frontiers in medicine 2026; (13()):1668375 doi:10.3389/fmed.2026.1668375.